Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm phase I study to determine the safety and preliminary
efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides
administered as a cancer-treatment vaccine to treat adult postoperative patients with
newly-diagnosed glioblastoma, in combination with the standard-of-care Temozolomide (TMZ)
chemotherapy.